Equities research analysts expect that Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) will announce earnings per share of ($1.69) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Apellis Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($1.22) and the lowest estimate coming in at ($1.90). Apellis Pharmaceuticals reported earnings per share of ($2.29) in the same quarter last year, which suggests a positive year over year growth rate of 26.2%. The business is scheduled to report its next quarterly earnings results on Wednesday, May 5th.
According to Zacks, analysts expect that Apellis Pharmaceuticals will report full-year earnings of ($6.48) per share for the current fiscal year, with EPS estimates ranging from ($8.07) to ($4.41). For the next financial year, analysts anticipate that the business will post earnings of ($5.47) per share, with EPS estimates ranging from ($6.68) to ($4.30). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Apellis Pharmaceuticals.
Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Wednesday, February 24th. The company reported $0.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $1.40. The company had revenue of $250.00 million during the quarter, compared to the consensus estimate of $184.54 million.
In related news, Director Alec Machiels sold 2,500 shares of the stock in a transaction dated Monday, March 15th. The stock was sold at an average price of $46.77, for a total transaction of $116,925.00. Following the completion of the sale, the director now owns 672,044 shares in the company, valued at $31,431,497.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Federico Grossi sold 600 shares of the stock in a transaction dated Thursday, April 1st. The stock was sold at an average price of $43.41, for a total value of $26,046.00. Following the sale, the insider now owns 56,714 shares of the company’s stock, valued at approximately $2,461,954.74. The disclosure for this sale can be found here. Insiders have sold 17,350 shares of company stock valued at $847,991 in the last quarter. 9.50% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers boosted its stake in Apellis Pharmaceuticals by 0.4% during the fourth quarter. Rhumbline Advisers now owns 74,511 shares of the company’s stock valued at $4,262,000 after buying an additional 312 shares during the last quarter. Los Angeles Capital Management LLC boosted its stake in Apellis Pharmaceuticals by 4.3% during the fourth quarter. Los Angeles Capital Management LLC now owns 8,805 shares of the company’s stock valued at $504,000 after buying an additional 365 shares during the last quarter. California State Teachers Retirement System boosted its stake in Apellis Pharmaceuticals by 0.4% during the third quarter. California State Teachers Retirement System now owns 90,923 shares of the company’s stock valued at $2,743,000 after buying an additional 377 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Apellis Pharmaceuticals by 15.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,950 shares of the company’s stock valued at $169,000 after buying an additional 400 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Apellis Pharmaceuticals by 2.7% during the fourth quarter. The Manufacturers Life Insurance Company now owns 36,278 shares of the company’s stock valued at $2,075,000 after buying an additional 940 shares during the last quarter. 81.20% of the stock is owned by institutional investors.
Apellis Pharmaceuticals stock traded up $0.01 during mid-day trading on Wednesday, hitting $46.00. The company had a trading volume of 614,513 shares, compared to its average volume of 642,671. The company has a market capitalization of $3.70 billion, a PE ratio of -6.20 and a beta of 1.47. The company has a current ratio of 9.86, a quick ratio of 9.86 and a debt-to-equity ratio of 3.34. Apellis Pharmaceuticals has a 12 month low of $25.49 and a 12 month high of $58.47. The stock’s 50 day moving average price is $44.43 and its two-hundred day moving average price is $45.01.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.